Dataset Information


Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells.

ABSTRACT: Novel approaches to pre-transplant conditioning are needed to improve treatment of advanced T-cell malignancies. We investigated the synergism of fludarabine (Flu), clofarabine (Clo), busulfan (Bu), and romidepsin (Rom) in T-cell lines and patient-derived cell samples. [Flu+Clo+Bu+Rom] had combination indexes of 0.4-0.5 at ?50% cytotoxicity in PEER and SUPT1 cells, suggesting synergism. Drug exposure resulted in histone modifications, DNA-damage response (DDR), increased reactive oxygen species (ROS), decreased glutathione (GSH) and mitochondrial membrane (MM) potential, and apoptosis. Similar activation of DDR and apoptosis was observed in patient samples. The PI3K-AKT-mTOR, NF?B, Raf-MEK-ERK, JAK-STAT and Wnt/?-catenin pro-survival pathways were inhibited by the 4-drug combination. The SAPK/JNK stress pathway was activated. A novel finding was the down-regulation of the drug transporter MRP1. We propose the following mechanisms of synergism: Flu, Clo and Rom induce histone modifications and chromatin remodeling, exposing DNA to Bu alkylation; the increased production of ROS, due to drug-mediated stress response and decreased GSH, damages the MM causing leakage of pro-apoptotic factors; down-regulation of MRP1 increases intracellular Bu concentration and exacerbates the DDR; and inhibition of multiple survival pathways. Our results provide the basis for a clinical trial to evaluate [Flu+Clo+Bu+Rom] as part of conditioning regimen for refractory T-cell malignancy patients undergoing stem cell transplantation.


PROVIDER: S-EPMC4961533 | BioStudies | 2016-01-01

REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC5325407 | BioStudies
2018-01-01 | S-EPMC5980696 | BioStudies
2018-01-01 | S-EPMC5743624 | BioStudies
2019-01-01 | S-EPMC6792289 | BioStudies
2016-01-01 | S-EPMC4949158 | BioStudies
2013-01-01 | S-EPMC3769691 | BioStudies
2015-01-01 | S-EPMC4490031 | BioStudies
2012-01-01 | S-EPMC3307734 | BioStudies
2014-01-01 | S-EPMC3966077 | BioStudies
1000-01-01 | S-EPMC4613962 | BioStudies